| Who is Euroscreen |
|
Euroscreen is a privately held preclinical-stage Drug Discover and Development Company based in Brussels Belgium, focused on small molecule drugs for unmet medical needs. Founded in 1994, as a spin-off of ULB (Université Libre de Bruxelles), initially developing and commercializing G Protein-Coupled Receptors (GPCR) reagents, Euroscreen has now proven itself in the field of GPCR drug discovery as demonstrated by its pipeline of preclinical drug candidates, including its global diabetes collaboration with Ortho-McNeil-Janssen Pharmaceuticals Inc. Euroscreen pursues a dual business model strategy of combining its internal programs for high value targets (Euroscreen DRUG DISCOVERY) with its services business unit (Euroscreen FAST) providing GPCR customized screening, cell lines and other services for biotech and pharmaceutical companies around the world. Euroscreen has also developed a broad target portfolio for licensing intellectual property rights to pharmaceutical companies for the development of therapeutic drugs that act through these targets, including CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2. See Patent Portfolio Euroscreen has discovery and licensing partnerships with Boehringer-Ingelheim, Grunenthal, HGS, Ortho-McNeil-Janssen Pharmaceuticals Inc., Monogram Biosciences, Novartis and Pfizer. See our Track Record |
About Euroscreen